Microenvironment-induced signaling pathways regulate the activity of numerous transcription factors (TFs). Approaches to target TFs are among the most promising novel anticancer strategies with a potentially high therapeutic index. Our recent data indicated a key role for the AP-1 family member JunB in MM pathogenesis (Fan et al., Leukemia 2017). In continuation of these findings, the proposed project aims to further define JunB as a novel therapeutic target in MM, and to thereby set the pace for the development of direct or indirect JunB inhibitors in order to further improve patient outcome.
Datum
|
1. 10. 2018 - 30. 9. 2021 |
Länderkürzel
|
AT |
Name der begünstigten Einrichtung
|
Karl Landsteiner Privatuniversität für Gesundheitswissenschaften GmbH |
Projektleitung
|
Abteilung für Innere Medizin 2 (UK Krems) |
Verknüpfung
|
www.kl.ac.at |
Förderrahmen & Förderprogramm
|
EFRE Österreich 2014-2020, Investitionen in Wachstum und Beschäftigung |
